TY - JOUR
T1 - The role of c-met as a biomarker and player in innate and acquired resistance in non-small-cell lung cancer
T2 - Two new mutations warrant further studies
AU - Van Der Steen, Nele
AU - Zwaenepoel, Karen
AU - Mazzaschi, Giulia
AU - Luirink, Rosa A.
AU - Geerke, Daan P.
AU - De Beeck, Ken Op
AU - Hermans, Christophe
AU - Tiseo, Marcello
AU - Van Schil, Paul
AU - Lardon, Filip
AU - Germonpré, Paul
AU - Rolfo, Christian
AU - Giovannetti, Elisa
AU - Peters, Godefridus J.
AU - Pauwels, Patrick
PY - 2019/12/4
Y1 - 2019/12/4
N2 - The c-Met receptor is a therapeutically actionable target in non-small-cell lung cancer (NSCLC), with one approved drug and several agents in development. Most suitable biomarkers for patient selection include c-Met amplification and exon-14 skipping. Our retrospective study focused on the frequency of different c-Met aberrations (overexpression, amplification and mutations) in 153 primary, therapy-naïve resection samples and their paired metastases, from Biobank@UZA. Furthermore, we determined the correlation of c-Met expression with clinicopathological factors, Epidermal Growth Factor Receptor (EGFR)-status and TP53 mutations. Our results showed that c-Met expression levels in primary tumors were comparable to their respective metastases. Five different mutations were detected by deep sequencing: Three (E168D, S203T, N375S) previously described and two never reported (I333T, G783E). I333T, a new mutation in the Sema(phorin) domain of c-Met, might influence the binding of antibodies targeting the HGF-binding domain, potentially causing innate resistance. E168D and S203T mutations showed a trend towards a correlation with high c-Met expression (p = 0.058). We found a significant correlation between c-MET expression, EGFR expression (p = 0.010) and EGFR mutations (p = 0.013), as well as a trend (p = 0.057) with regards to TP53 mutant activity. In conclusion this study demonstrated a strong correlation between EGFR mutations, TP53 and c-Met expression in therapy-naïve primary resection samples. Moreover, we found two new c-Met mutations that warrant further studies.
AB - The c-Met receptor is a therapeutically actionable target in non-small-cell lung cancer (NSCLC), with one approved drug and several agents in development. Most suitable biomarkers for patient selection include c-Met amplification and exon-14 skipping. Our retrospective study focused on the frequency of different c-Met aberrations (overexpression, amplification and mutations) in 153 primary, therapy-naïve resection samples and their paired metastases, from Biobank@UZA. Furthermore, we determined the correlation of c-Met expression with clinicopathological factors, Epidermal Growth Factor Receptor (EGFR)-status and TP53 mutations. Our results showed that c-Met expression levels in primary tumors were comparable to their respective metastases. Five different mutations were detected by deep sequencing: Three (E168D, S203T, N375S) previously described and two never reported (I333T, G783E). I333T, a new mutation in the Sema(phorin) domain of c-Met, might influence the binding of antibodies targeting the HGF-binding domain, potentially causing innate resistance. E168D and S203T mutations showed a trend towards a correlation with high c-Met expression (p = 0.058). We found a significant correlation between c-MET expression, EGFR expression (p = 0.010) and EGFR mutations (p = 0.013), as well as a trend (p = 0.057) with regards to TP53 mutant activity. In conclusion this study demonstrated a strong correlation between EGFR mutations, TP53 and c-Met expression in therapy-naïve primary resection samples. Moreover, we found two new c-Met mutations that warrant further studies.
KW - Biomarkers
KW - C-Met
KW - EGFR
KW - NSCLC
UR - http://www.scopus.com/inward/record.url?scp=85076355617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076355617&partnerID=8YFLogxK
U2 - 10.3390/molecules24244443
DO - 10.3390/molecules24244443
M3 - Article
C2 - 31817278
AN - SCOPUS:85076355617
VL - 24
JO - Molecules
JF - Molecules
SN - 1420-3049
IS - 24
M1 - 4443
ER -